Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onalespib with Dabrafenib and Trametinib in BRAF-Mutant Solid Tumors
NCT02097225Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of onalespib in solid tumor and melanoma (5 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Dabrafenib at 28 days, Maximum Tolerated Dose of Trametinib at 28 days and 2 more. Started May 2014; status: terminated.
02
Drugs
onalespib
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT02097225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097225.